Dogwood Therapeutics, Inc. (DWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.27 Million) by net assets ($77.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dogwood Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DWTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Dogwood Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FASOO.COM Co Ltd
KQ:150900
|
0.031x |
|
Hai Phong Hoang Ha Paper JSC
VN:HHP
|
N/A |
|
Uniflex Technology Inc
TW:3321
|
-0.422x |
|
Sino Tactful Co Ltd
TWO:5481
|
-0.014x |
|
Milae Bioresources Co. Ltd
KQ:218150
|
0.017x |
|
Bonia Corporation Bhd
KLSE:9288
|
0.021x |
|
Barratt Redrow plc
LSE:BTRW
|
-0.043x |
|
Alpha Exploration Ltd
V:ALEX
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Dogwood Therapeutics, Inc. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see DWTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $64.28 Million | $-8.79 Million | -0.137x | +89.31% |
| 2023-12-31 | $3.81 Million | $-4.87 Million | -1.279x | +18.26% |
| 2022-12-31 | $7.33 Million | $-11.47 Million | -1.565x | -44.67% |
| 2021-12-31 | $14.50 Million | $-15.69 Million | -1.082x | -731.66% |
| 2020-12-31 | $29.94 Million | $-3.90 Million | -0.130x | -130.73% |
| 2019-12-31 | $-4.94 Million | $-2.09 Million | 0.423x | -55.39% |
| 2018-12-31 | $-1.26 Million | $-1.20 Million | 0.949x | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more